Vaccine news, ETF reductions drive gold correction risk

Commodities 5 minutes to read
Ole Hansen

Head of Commodity Strategy

Summary:  Gold continues to lose momentum in response to recent vaccine announcements and their potential effectiveness in combatting a not-yet-under-control Covid-19 outbreak. This development has driven a small exodus out of exchange-traded funds with total holdings down 1.7 million ounces or 1.5% to a 2-1/2-month low. While the short-term outlook has turned somewhat challenging, the medium term outlook remains favorable for gold and other investment metals.


Gold continues to lose momentum in response to recent vaccine announcements and their potential effectiveness in combatting a not-yet-under-control Covid-19 outbreak. In fact today we are seeing emerging market currencies as well as stock indexes retreating from their recent run of gains amid concerns about tougher restrictions to curb the resurgent coronavirus pandemic.

Despite of this gold remains on the defensive with the loss of momentum attracting selling from Exchange-traded funds backed by bullion. Yesterday total holdings dropped by 322,000 ounces and since the Pfizer/BioNTech announcement on November 9, total holdings have fallen by 1.7 million ounces to 109.4 million, a 2-1/2-month low.

While these developments may further add to the risk of a deeper correction, it is worth keeping in mind that ETF flows are more often lagging instead of leading the price action. As we have highlighted in previous updates, the vaccine can kill the virus but not the mountain of debt that has been accumulated this year. Central banks are expected to maintain ultraloose monetary conditions, which inadvertently may lead to rising risk of higher inflation through a policy mistake in not reacting sooner to the eventual recovery.

Apart from the risk of rising inflation providing medium-term support to gold, another key driver for commodities in general and especially precious metals, remains the inverse correlation to the dollar. Analysts at the big banks predict that the dollar could fall 20% if widely available coronavirus jab leads to an economic rebound in 2021. This according to an article in the $FT today called “Vaccine arrival expected to trigger dollar slump in 2021”.

The short-term outlook however remains challenged by a deteriorating technical outlook and the mentioned withdrawals from Exchange-traded funds. As per the chart below, the recent price action has seen a bear-flag emerge and a break below $1850/oz carries the risk of a deeper correction towards $1837/oz, the 38.2% retracement of the March to August rally or even down to the 200-day moving average at $1790/oz.

While short-term technical traders and algorithmic trading system may sell into the current weakness, investors with a longer term view are – in our opinion - likely to take the opportunity to accumulated at lower levels.

Source: Saxo Group
Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide and Product Disclosure Statement to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.
Please click here to view our full disclaimer.